Přejít na obsah
PFEPFE
Zpět na vyhledávání
PFE
PFENYSE

Pfizer Inc.

Healthcare•United States
28,41 US$
+0,23 US$ (+0,82 %)

Tažením v grafu vyberte úsek a zobrazí se procentuální změna.Tažením dvěma prsty vyberte úsek a zobrazí se procentuální změna.

Kapitálová struktura

Tržní kapitalizace
161,93 mld. US$
Enterprise Value
212,69 mld. US$
Hotovost
11,7 mld. US$
Celkový dluh
63,48 mld. US$
Čistý dluh
51,78 mld. US$

Valuace (TTM)

P/E
37,38×
P/E (fwd)
9,81×
P/FCF
14,74×
FCF výnos
6,78 %
EV/EBITDA
8,38×
P/S
—
P/B
1,90×
Beta
0,30

Marže (TTM)

Hrubá marže
74,72 %
EBITDA marže
39,85 %
Provozní marže
27,88 %
Čistá marže
6,80 %
FCF marže
17,25 %

Ziskovost a růst

ROE (rentabilita kapitálu)
5,01 %
Růst tržeb (YoY)
2,60 %
Růst zisku (YoY)
—

Dividenda

Dividendový výnos
6,10 %
Roční dividenda
1,72 US$
Výplatní poměr
226,32 %
Datum ex-dividendy
2026-07-24

52týdenní rozpětí

23,58 US$29,21 US$
Aktuální
28,41 US$
Pozice v pásmu
86 %
Nad ročním minimem
+20,48 %
Pod ročním maximem
-2,74 %

Cena v kontextu

-53,62 %od historického maxima
Historické maximum
61,25 US$
Datum maxima
16. 12. 2021
Zpět na maximum
+115,59 %
200denní průměr
26,31 US$
Odchylka od průměru
+7,98 %

O společnosti

Web

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Vedení společnosti

Dr. Albert Bourla D.V.M., Ph.D.
Generální ředitel (CEO)
  • Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development
  • Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer
  • Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer
  • Ms. Cecile GueganInterim CFO & Executive VP
  • Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer
  • Mr. Dennis P. HancockExecutive VP & Chief Information Officer
  • Ms. Francesca M. DeMartinoChief Investor Relations Officer
  • Ms. Payal Sahni BecherChief People Experience Officer & Executive VP
  • Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology